Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market CAGR Outlook And Future Development
The warm autoimmune hemolytic anemia (waiha) treatment market has demonstrated significant growth in size over recent years. It is projected to expand from $0.6 billion in 2025 to $0.65 billion in 2026, achieving a compound annual growth rate (CAGR) of 9.2%. The growth observed in prior periods can be attributed to factors such as reliance on corticosteroid therapy, limited treatment options, hospital-based autoimmune care, blood transfusion dependency, and low disease awareness.
The market size for warm autoimmune hemolytic anemia (waiha) treatments is anticipated to experience substantial growth in the upcoming years. It is projected to expand to $0.93 billion by 2030, achieving a compound annual growth rate (CAGR) of 9.2%. The expansion during this forecast period can be attributed to advancements in biologic drugs, improved diagnostics for autoimmune conditions, the broadening application of precision medicine, an increasing geriatric population, and the growth of specialty hematology care. Significant trends expected during the forecast period include a greater utilization of monoclonal antibody therapies, the increasing adoption of steroid-sparing treatments, an expansion of personalized autoimmune therapies, the rising importance of IVIG in acute management, and enhanced diagnostic and monitoring protocols.
Get A Free Sample Report With In-Depth Market Insights:
Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market Growth Factors: What’s Supporting Expansion?
Rising healthcare spending is anticipated to stimulate the expansion of the warm autoimmune hemolytic anemia (WAIHA) treatment market in the future. Healthcare expenditure encompasses the complete sum of funds allocated to health services, covering disease prevention, diagnosis, treatment, and management, by individuals, governmental bodies, and various organizations. Progress in medical technology is elevating healthcare spending, given that modern diagnostic methods and therapies frequently involve greater expenses for their development, deployment, and continuous patient support. This spending on healthcare bolsters warm autoimmune hemolytic anemia (WAIHA) treatment through financing research, enabling access to sophisticated diagnostic instruments, and securing specialized treatments essential for managing and controlling the condition. For example, in May 2024, data from the Office for National Statistics, a UK-based government agency, indicated that long-term health and social care expenditures saw a real-term increase of 2.8% in 2022, while total healthcare spending rose by 5.6% in 2023. Consequently, the growing healthcare expenditure is propelling the expansion of the warm autoimmune hemolytic anemia (WAIHA) treatment market.
Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market Segment Analysis And Revenue Potential
The warm autoimmune hemolytic anemia (waiha) treatment market covered in this report is segmented –
1) By Treatment Type: Corticosteroids, Monoclonal Antibodies, Intravenous Immunoglobulin (IVIG), Blood Transfusions, Splenectomy
2) By Route Of Administration: Oral, Intravenous, Subcutaneous
3) By Patient Demographics: Children, Adults, Geriatric
4) By Therapeutic Area: Primary Autoimmune Disorders, Secondary Autoimmune Disorders, Genetic Predisposition
5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Corticosteroids: Prednisone, Dexamethasone, Methylprednisolone
2) By Monoclonal Antibodies: Rituximab, Sutimlimab, Bortezomib
3) By Intravenous Immunoglobulin: Standard IVIG, High-Dose IVIG Therapy, Pooled Plasma-Derived Immunoglobulins
4) By Blood Transfusions: Leukoreduced RBC Transfusions, Emergency Transfusions, Phenotypically Matched RBC Transfusions
5) By Splenectomy: Laparoscopic Splenectomy, Prophylactic Treatments Post-Splenectomy, Open Splenectomy
Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market Industry Trends: What’s Reshaping Demand?
Leading companies in the warm autoimmune hemolytic anemia (WAIHA) treatment market are actively developing innovative solutions, such as monoclonal antibodies, to address outstanding clinical needs and enhance patient results. Monoclonal antibodies are proteins engineered in laboratories designed to target specific immune cells or pathways, thereby reducing the breakdown of red blood cells in warm autoimmune hemolytic anemia. For instance, in July 2023, IASO Biotechnology, a China-based biopharmaceutical company, announced the U.S. Food and Drug Administration (FDA) approval of its IASO-782 Injection for clinical studies within the United States for autoimmune hematological conditions, including warm autoimmune hemolytic anemia (WAIHA) and primary immune thrombocytopenia (ITP). This fully human monoclonal antibody targets CD19 and incorporates Fc mutations to boost ADCC activity while preserving other Fc functions. It specifically depletes CD19+ B cells, plasma blasts, and certain plasma cells that are responsible for generating auto-reactive antibodies. Given its unique mechanism, IASO-782 holds potential for treating autoimmune diseases driven by pathogenic B and plasma cells, such as ITP and AIHA.
Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market Key Players Shaping Industry Direction
Major companies operating in the warm autoimmune hemolytic anemia (waiha) treatment market are F. Hoffmann-La Roche Ltd., Sanofi S.A., Novartis AG, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Agios Pharmaceuticals Inc., Incyte Corporation, Mallinckrodt Pharmaceuticals, Xencor Inc., Annexon Inc., Rigel Pharmaceuticals Inc., Apellis Pharmaceuticals Inc., Momenta Pharmaceuticals Inc., Immunovant Inc., Zenas BioPharma Inc., Alexion Pharmaceuticals Inc., CSL Behring, Grifols S.A., Octapharma AG, Kedrion Biopharma, LFB Group, ADMA Biologics Inc., Pfizer Inc., Bristol-Myers Squibb Company, Amgen Inc.
View The Full Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market Report:
Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market Largest Region: Which Geography Holds The Highest Market Share?
North America was the largest region in the warm autoimmune hemolytic anemia (WAIHA) treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the warm autoimmune hemolytic anemia (waiha) treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Leave a Reply